Special Issue

Pandemic Influenza Vaccination

Message from the Guest Editors

Pandemic influenza vaccines are crucial tools in mitigating the impact of influenza pandemics. These vaccines can also play an important role during the interpandemic period to prevent zoonotic infection with H5 viruses in populations at elevated risk and to respond to isolated outbreaks. The 2009 influenza pandemic and the more recent COVID-19 pandemic have highlighted the importance of pandemic planning and preparedness; this includes having an updated national pandemic plan as well as a deployment and vaccination plan. This also includes strengthening national capacities for the early detection, research, regulatory approval, rollout, and monitoring of pandemic influenza vaccinations. These capacities are crucial for an effective and timely response to an influenza pandemic. In light of the above, this Special Issue will have two significant emphases: 1, the development. production, licensing, and procurement of influenza vaccines; 2. influenza vaccinations during epidemics and pandemics, including preparing for and delivering successful campaigns.

Guest Editors

Dr. Francisco Nogareda

Special Program Comprehensive Immunization, Pan American Health Organization (PAHO)/World Health Organization (WHO), Washington, DC 20037, USA

Dr. Shoshanna Goldin

World Health Emergencies Program, World Health Organization (WHO), 1211 Geneva, Switzerland

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/229421

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

